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Targeted Inhibition of Aggrecanases Prevents Articular 
Cartilage Degradation and Augments Bone Mass in the 
STR/Ort Mouse Model of Spontaneous Osteoarthritis
Ioannis Kanakis,1  Ke Liu,1 Blandine Poulet,1  Behzad Javaheri,2  Rob J. van ’t Hof,1   
Andrew A. Pitsillides,2  and George Bou-Gharios1
Objective. Cartilage destruction in osteoarthritis (OA) is mediated mainly by matrix metalloproteinases (MMPs) 
and ADAMTS. The therapeutic candidature of targeting aggrecanases has not yet been defined in joints in which 
spontaneous OA arises from genetic susceptibility, as in the case of the STR/Ort mouse, without a traumatic or load- 
induced etiology. In addition, we do not know the long- term effect of aggrecanase inhibition on bone. We undertook 
this study to assess the potential aggrecanase selectivity of a variant of tissue inhibitor of metalloproteinases 3 
(TIMP- 3), called [- 1A]TIMP- 3, on spontaneous OA development and bone formation in STR/Ort mice.
Methods. Using the background of STR/Ort mice, which develop spontaneous OA, we generated transgenic mice 
that overexpress [- 1A]TIMP- 3, either ubiquitously or conditionally in chondrocytes. [- 1A]TIMP- 3 has an extra alanine 
at the N- terminus that selectively inhibits ADAMTS but not MMPs. We analyzed a range of OA- related measures in 
all mice at age 40 weeks.
Results. Mice expressing high levels of [- 1A]TIMP- 3 were protected against development of OA, while those ex-
pressing low levels were not. Interestingly, we also found that high levels of [- 1A]TIMP- 3 transgene overexpression 
resulted in increased bone mass, particularly in females. This regulation of bone mass was at least partly direct, as 
adult mouse primary osteoblasts infected with [- 1A]TIMP- 3 in vitro showed elevated rates of mineralization.
Conclusion. The results provide evidence that [- 1A]TIMP- 3–mediated inhibition of aggrecanases can protect 
against cartilage degradation in a naturally occurring mouse model of OA, and they highlight a novel role that aggre-
canase inhibition may play in increased bone mass.
INTRODUCTION
Osteoarthritis (OA) is characterized by altered homeostasis of 
articular cartilage and abnormal bone formation. OA development 
depends on a balance of extracellular matrix (ECM) production 
and degradation. Proteolytic enzymes such as ADAMTS as well 
as matrix metalloproteinases (MMPs) are found to be up- regulated 
in OA joints (1–5) and are directly involved in OA pathophysiol-
ogy (6,7). Therefore, inhibition of these metalloproteinases is a 
potential route for the design of pharmaceutical agents to retard, 
suppress, and even halt the progression of OA. However, broad- 
spectrum inhibitors of MMPs, which were shown to be chondro-
protective in animal models, raised safety concerns in a clinical 
trial, pinpointing a need for inhibitors with greater specificity (8). 
In C57BL/6 mice, loss of activity of key catabolic enzymes, such 
as ADAMTS- 5, protects against OA lesions (9–11) compared 
with deletion of ADAMTS- 1 or ADAMTS- 4, which suggests that 
ADAMTS- 5 plays a central role in mouse models of inflammatory- 
and surgically induced OA (12,13). However, more recent data 
suggest that another aggrecanase, not yet determined, cleaves 
aggrecan before its secretion. Moreover, a noncatalytic function 
of ADAMTS- 5 is suggested to have competitive interactions with 
major endocytic recycling machinery (14).
Investigators using STR/Ort mice as a model of human OA 
have proved that genetic susceptibility is a solid basis for assess-
ing the protection afforded by novel treatment (15,16). Crucially, 
OA in STR/Ort mice closely resembles human OA and progresses 
to cartilage loss, along with similar alterations in bone mass and 
structure (17–20). Pertinently, it has been shown that the OA- 
related proteoglycan depletion observed predominantly across 
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the medial tibial compartment in STR/Ort mouse joints also 
likely involves both collagenase and aggrecanase activities, as 
in humans (20,21). Interestingly, compared with C57BL/6 mice, 
female STR/Ort mice have high bone mass, with bone marrow 
compression and extramedullary hematopoiesis observed by 
age 36 weeks (22). Consistently, recent studies from our group 
showed that this difference is present even in young STR/Ort 
mice, which have increased cortical and trabecular parameters 
compared with age- matched CBA mice (23). These character-
istics make the STR/Ort strain an intriguing and hitherto unex-
plored target in which to explore potentially protective transgenic 
 strategies.
Tissue inhibitor of metalloproteinases 3 (TIMP- 3) is a native 
biologic inhibitor of enzyme activity for members of the metzincin 
family, including collagenases (MMPs 1, 8, and 13), gelatinases 
(MMPs 2 and 9), and aggrecanases (ADAMTS- 4 and ADAMTS- 5). 
Extracellular trafficking of TIMP- 3 is regulated by the competition 
between ECM binding and endocytosis via low- density lipopro-
tein receptor–related protein 1 (LRP- 1) (24–26). It has previously 
been shown that modifications in TIMP- 3 expression could modify 
joint degeneration (27) and that loss/gain of TIMP- 3 function leads 
to significant alteration in bone structure (28,29). In the present 
study, we have used a variant of TIMP- 3, named [- 1A]TIMP- 3, 
which harbors a single alanine addition to the amino- terminal end, 
which was shown to inhibit aggrecanases, namely ADAMTS- 4/5, 
with much greater selectivity than other MMPs (30,31). This mod-
ified activity is driven by conformational changes, in which the 
active site is tilted and the interaction of Phe34 of the inhibitor with 
MMPs is lost (31).
Our aim was to assess the potential aggrecanase selectivity 
of [- 1A]TIMP- 3 on spontaneous OA development and bone for-
mation in STR/Ort mice. We found that high levels of [- 1A]TIMP- 3 
expression in transgenic STR/Ort mice can effectively attenuate 
cartilage destruction and OA- related subchondral thickening, but, 
strikingly, can also significantly augment bone mass.
MATERIALS AND METHODS
Generation of lentiviral and plasmid vectors to over-
express [- 1A]TIMP- 3. The lentivirus vector was constructed by 
cloning [- 1A]TIMP- 3 with a FLAG tag into the Eco RV–Sal I site of 
the pCCL- expressing vector driven by the elongation factor 1α 
(EF- 1α) promoter. The construct also contained nerve growth fac-
tor receptor (NGFR) as a marker (Figure 1A).
We cotransfected 293T17 cells with transfer vector and 
packaging vectors by electroporation using a Neon transfection 
system (Invitrogen) to produce the virus. Viral supernatants were 
harvested 48 and 72 hours after transfection and concentrated 
by ultracentrifugation at 10,000g for 2 hours. The viral pellet was 
collected and dissolved in phosphate buffered saline (PBS).
A second conditional plasmid was generated using the 
Col2a1 3- kb promoter and the 3- kb first intron that drives specific 
expression in chondrocytes (32). The [- 1A]TIMP- 3 complementary 
DNA (cDNA) was followed by an internal ribosome entry site and 
a β- galactosidase reporter gene (Figure 1B).
Transient transduction was performed at 10 multiplicities 
of infection in 2 cell lines, HEK 293 and HTB94, to test integra-
tion efficacy and overexpression capacity. Flow cytometry with 
allophycocyanin- conjugated anti- NGFR was used to estimate 
transfection efficiency. Trichloroacetic acid (TCA) protein precipi-
tation and Western blotting were used to test [- 1A]TIMP- 3 protein 
levels.
Animals. An STR/Ort mouse colony maintained at Royal 
Veterinary College, London was used to generate transgenic mice 
overexpressing [- 1A]TIMP- 3 on this background. Each fertilized 
embryo was injected with either Col2a1[- 1A]TIMP- 3 linearized 
plasmid in male pro nucleus or by infection using 100 lentiviral 
particles (EF- 1α[- 1A]TIMP- 3) per embryo. The latter procedure 
was also used to generate transgenic mice in the control CBA 
strain (EF- 1α[- 1A]TIMP- 3–transgenic CBA mice). Newborn trans-
genic mice were routinely genotyped by quantitative polymerase 
chain reaction (qPCR) using the reporter gene LacZ as well as the 
[- 1A]TIMP- 3 insert (see Supplementary Table 1, available on the 
Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.40765/abstract). All experimental protocols were 
performed in compliance with the UK Animals (Scientific Proce-
dures) Act 1986 regulations.
We analyzed hind limb bones and knee joints isolated from 
STR/Ort mice at age 40 weeks. Age- matched nontransgenic 
(untreated) STR/Ort mice or transgenic CBA mice, a parental 
background strain of STR/Ort mice, were used as controls. The 
exact number of animals used in each analysis is described in Sup-
plementary Table 2, http://onlinelibrary.wiley.com/doi/10.1002/art. 
40765/abstract.
Western blotting. Cultured media from transfected HEK 
293 and HTB94 cells were precipitated with TCA, resuspended 
in PBS to equal total protein content, resolved by 10% sodium 
dodecyl sulfate–polyacrylamide gel electrophoresis under reduc-
ing conditions, and electrotransferred to Hybond P PVDF mem-
branes (Amersham Biosciences). Membranes were blocked with 
5% skim milk and probed overnight at 4°C with rabbit polyclonal 
anti–TIMP- 3 antibody (1:2,000 dilution, AB6000; Millipore), fol-
lowed by incubation with horseradish peroxidase (HRP)–labeled 
goat anti- rabbit antibody (1:10,000 dilution; Dako). Analysis was 
performed using an ECL Advanced Western Blotting Detection 
Kit (Amersham Biosciences). For Western blots using mouse 
tails, 250 mg of tissue was boiled at 95°C for 10 minutes in 
Laemmli buffer, and samples were electrophoresed in 4–12% 
Bis- Tris precast gels (NuPAGE) at 200V for 35 minutes. Proteins 
were transferred on PVDF membranes, blocked, and incubated 
overnight with either anti–TIMP- 3 antibody or rabbit anti–β- actin 
(ab8227; Abcam). Detection was performed using fluorescent 
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goat  anti- rabbit  secondary antibodies (IRDye 680RD for actin and 
800CW for TIMP- 3; Li- Cor), and relative quantitation was con-
ducted with β- actin as a reference protein.
Quantitative PCR. Integration of [- 1A]TIMP- 3 cDNA and 
overexpression were monitored by qPCR at both genomic DNA 
and messenger RNA (mRNA) levels (for details, see Supple-
mentary Methods, http://onlinelibrary.wiley.com/doi/10.1002/
art.40765/abstract).
Micro–computed tomography (micro- CT). Left and right 
hind limbs of all STR/Ort mice were dissected and  immediately 
Figure  1. Evaluation of lentiviral expression. A and B, Illustrations of constructed vectors for overexpression of the tissue inhibitor 
of metalloproteinases 3 (TIMP- 3) variant [- 1A]TIMP- 3 with lentivirus (LV)–driven elongation factor 1α (EF- 1α) promoter (A) and conditional 
Col2a1- driven transductions (B) are shown. C, Chondrocytic HTB94 cells, analyzed by flow cytometry, show increased expression of nerve 
growth factor receptor (NGFR) in cells expressing the lentiviral transgene. APC = allophycocyanin. D, Western blots of HTB94 cells show 
small quantities of endogenous TIMP- 3 in lentiviral empty vector (LV- empty) compared with high protein levels in both HEK 293 and HTB94 
[- 1A]TIMP- 3–overexpressing cells (LV- [- 1A]TIMP- 3). E, Integration of [- 1A]TIMP- 3 into genomic DNA (gDNA) extracted from ear notches 
in all mice was evaluated by quantitative polymerase chain reaction. STR/Ort mice in the Col2a1[- 1A]TIMP- 3–transgenic group expressed 
significantly lower levels of [- 1A]TIMP- 3 compared with EF- 1α[- 1A]TIMP- 3–transgenic CBA control mice. NS = not significant. F, Quantification 
of [- 1A]TIMP- 3 mRNA in femoral heads of STR/Ort mice showed higher expression in EF- 1α[- 1A]TIMP- 3–transgenic mice. Mice were separated 
according to high and low levels of [- 1A]TIMP- 3 mRNA expression, with a cutoff value of 2- fold difference. G, Males expressed lower levels of 
[- 1A]TIMP- 3 than did females in both transgenic groups, and the difference was significant in Col2a1[- 1A]TIMP- 3–transgenic mice. H, Western 
blot confirmed increasing levels of [- 1A]TIMP- 3 protein in STR/Ort mice expressing higher amounts of [- 1A]TIMP- 3 mRNA compared with STR/
Ort mice expressing lower amounts of [- 1A]TIMP- 3 mRNA and compared with wild- type (WT) mice. In E–G, symbols represent individual mice; 
bars show the mean ± SD. * = P < 0.05; *** = P < 0.001; **** = P < 0.0001.
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scanned using a Skyscan 1272 micro- CT scanner (Bruker) at 
50 kV, 0.5 aluminum filter, 200 mA, voxel size 9.00 μm, and 0.3° 
rotation angle. Data sets were reconstructed using NRecon recon-
struction software, and 3- dimensional volumes of interest were 
selected using Dataviewer and CTAn software. Morphometric 
parameters were analyzed for tibial metaphyseal trabecular bone, 
cortical bone in diaphysis, and subchondral bone in epiphysis 
as previously described (33,34) (for details, see Supplementary 
Methods, http://onlinelibrary.wiley.com/doi/10.1002/art.40765/
abstract).
In vitro bone cell culture and mineralization assay. 
STR/Ort and CBA mouse–derived primary osteoblasts were iso-
lated, and their mineralization capacity was assessed by alizarin 
red S staining after 4 weeks. To assess the in vitro osteoregula-
tory effect of [- 1A]TIMP- 3, osteoblasts were isolated from skel-
etally mature 12- week- old wild- type (WT) C57BL/6 mice and 
infected with [- 1A]TIMP- 3 or TIMP- 3 lentiviruses, while untreated 
and lentivirus–mock- infected osteoblasts served as controls. 
Early mineralization capacity of the infected osteoblasts was 
evaluated with alizarin red S staining after 21 days (for details, 
see Supplementary Methods, http://onlinelibrary.wiley.com/
doi/10.1002/art.40765/abstract).
Histologic evaluation of cartilage lesions in STR/
Ort mice. Following micro- CT, knee joints from all STR/Ort 
mice were fixed in 4% paraformaldehyde solution for 24 hours, 
decalcified in 10% EDTA for 3 weeks, and subsequently stored 
in 70% ethanol until processing. Samples were embedded in 
paraffin wax and sectioned coronally (5 μm thickness) through 
the entire joint. Proteoglycan loss was evaluated using Safranin 
O–fast green staining and a validated scoring system following 
the Osteoarthritis Research Society International (OARSI) rec-
ommendations (35). Joints were scored in a blinded manner by 
2 experienced investigators (IK and BP), and scores were aver-
aged using a modification to the methods of Poulet et al (18). To 
obtain robust results, as OA affects predominantly the medial 
tibial plateau and medial femoral condyle, the average of the 
maximum scores at both sites was used for each sample. Mean 
scores were calculated as the average of the scores recorded at 
8 levels at 90- μm intervals across the entire joint.
Immunohistochemistry. For immunohistochemistry 
experiments, sections were deparaffinized, rehydrated, and 
probed with selected antibodies. Two percent normal goat serum 
was used for blocking. For [- 1A]TIMP- 3 detection, an additional 
step of antigen retrieval was applied by incubation with chondroit-
inase ABC (Sigma) at 0.01 units/ml. Rabbit anti- mouse TIMP- 3 
polyclonal antibody against the C- terminus of TIMP- 3 (Millipore) 
was used at 1:3,000 dilution in normal goat serum. Rabbit anti- 
mouse anti- NVTEGE antibody (1:850), kindly provided by Dr. 
J. S. Mort (36), was used for detection of ADAMTS- generated 
neoepitopes. Nonimmune rabbit serum was used as negative 
control. Primary antibodies were detected using a Vectastain 
ABC kit with a secondary goat anti- rabbit biotinylated antibody 
(Vector) and visualized with HRP- conjugated streptavidin using 
3,3′- diaminobenzidine.
Statistical analysis. All data were analyzed with Graph-
Pad Prism 6 software and expressed as the mean ± SD. Data 
sets were tested for Gaussian distribution with the D’Agostino- 
Pearson normality test. Comparisons between ≥3 groups were 
performed by one- way analysis of variance followed by Tukey’s 
multiple comparisons post hoc test. The Mann- Whitney U test or 
Student’s 2- tailed t- test was used to compare 2 groups. Corre-
lations were performed with Pearson’s test. In all cases, P values 
less than 0.05 were considered significant.
RESULTS
In vitro efficacy of [- 1A]TIMP- 3 lentiviral transduc-
tion. In order to evaluate efficacy of lentiviral transduction, we 
infected the human embryonic kidney cell line (HEK 293) as well 
as the chondrosarcoma HTB94 cell line with a lentiviral construct 
(Figure 1A). Approximately 75% of HTB94 cells transduced with 
the [- 1A]TIMP- 3–containing vector expressed the NGFR marker, 
which is coexpressed by the same vector; in contrast, there was 
no detectible NGFR marker expression in uninfected control 
HTB94 cells (Figure 1C).
Western blot analysis showed that control HTB94 cells 
transduced by empty lentiviral vector secreted a small amount 
of endogenous TIMP- 3 protein into the medium, detected by the 
anti–TIMP- 3 antibody. In contrast, a high level of [- 1A]TIMP- 3 pro-
tein was secreted by HTB94 cells infected with EF- 1α[- 1A]TIMP- 3 
lentivirus compared with a lower level of protein from HEK 293 
cells (Figure 1D). The data demonstrate effective lentivirus trans-
duction into different types of cells and overexpression of the [- 1A]
TIMP- 3 transgene in chondrocytes.
Transgenic overexpression of [- 1A]TIMP- 3 in mice. 
We generated several transgenic lines using 2 different meth-
ods. Lentivirus- induced global [- 1A]TIMP- 3–transgenic mice 
(EF- 1α[- 1A]TIMP- 3–transgenic mice) were compared with con-
ditional Col2a1[- 1A]TIMP- 3–transgenic mice. The method of 
pronuclear injection of fertilized STR/Ort mouse eggs using 
Col2a1[- 1A]TIMP- 3 linearized plasmid resulted in a low level 
of integration of the transgene, as determined by qPCR of 
genomic DNA from ear notches (Figure 1E). In order to deter-
mine mRNA expression levels within STR/Ort transgenic mice, 
total RNA was extracted from whole mouse femoral heads. 
Quantitative PCR using a specific primer for FLAG tag at the 
3′- end of [- 1A]TIMP- 3 to distinguish endogenous from trans-
genic mRNA resulted in a range of mRNA overexpression, 
ranging between a ≤2- fold and a 13- fold increase (Figure 1F). 
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Most mice expressing high levels of [- 1A]TIMP- 3 mRNA were 
generated from lentiviral infection. [- 1A]TIMP- 3 mRNA levels 
were consistent across paired left and right femoral heads in 
both EF- 1α[- 1A]TIMP- 3– and Col2a1[- 1A]TIMP- 3–transgenic 
groups of mice, but lower levels of expression were noted 
in males compared with females, especially in those of the 
Col2a1[- 1A]TIMP- 3–transgenic group, perhaps because of 
smaller group size (Figure  1G). Western blot showed unde-
tectable [- 1A]TIMP- 3 protein levels in WT and low expressers 
but 5–10- fold greater levels in mice deemed high expressers 
based on an assessment of their [- 1A]TIMP- 3 mRNA levels 
(Figure 1H).
Figure 2. Overexpression of [- 1A]TIMP- 3 protects against osteoarthritis (OA) cartilage degradation in STR/Ort mice. A–C, Untreated STR/
Ort mice at age 40 weeks show severe OA erosion in the medial sites of the tibial plateau and femoral condyles (circled in A), while both EF- 
1α[- 1A]TIMP- 3–transgenic mice (B) and Col2a1[- 1A]TIMP- 3–transgenic mice (C) show cartilage protection. D and E, OA scores of both EF- 
1α[- 1A]TIMP- 3–transgenic mice and Col2a1[- 1A]TIMP- 3–transgenic mice were significantly lower than those of age- matched untreated STR/
Ort mice, which had high maximum (D) and mean (E) OA scores of the knee joints. MTP = medial tibial plateau; MFC = medial femoral condyle. 
F and G, Significant negative correlations between [- 1A]TIMP- 3 expression levels and OA scores were found in Col2a1[- 1A]TIMP- 3–transgenic 
mice (F) and EF- 1α[- 1A]TIMP- 3–transgenic mice (G), which suggests that mice expressing high levels of [- 1A]TIMP- 3 (solid symbols) were better 
protected than those expressing low levels of [- 1A]TIMP- 3 (open symbols). H–J, Subchondral bone thickness was assessed by micro–computed 
tomography, which demonstrated that untreated STR/Ort mice with OA had severe sclerotic lesions (arrow) at the medial side of the tibial epiphysis 
(H) compared with EF- 1α[- 1A]TIMP- 3–transgenic mice (I) and Col2a1[- 1A]TIMP- 3–transgenic mice (J). K, Quantification of subchondral bone 
thickness showed significant reduction on the medial site, while the lateral site seemed unaffected. In D, E, and K, symbols represent individual 
mice; bars show the mean ± SD. * = P < 0.05; ** = P < 0.01; **** = P < 0.0001. See Figure 1 for other definitions and explanation of cutoff.
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Overall, STR/Ort background transgenic mice were harder 
to generate by direct pronuclear injection as fewer eggs were fer-
tilized compared with CBA control mice and significant numbers 
of injected eggs did not survive. Importantly, the various levels 
of transgene expression achieved allowed us to determine the 
“threshold” expression level of [- 1A]TIMP- 3 needed for effective 
amelioration of the STR/Ort phenotype.
[- 1A]TIMP- 3 protects against OA cartilage degrada-
tion in STR/Ort mice. The main OA features in the STR/Ort 
mouse knee are cartilage loss on the medial tibial plateau and 
medial femoral condyle accompanied by osteophyte develop-
ment and subchondral bone sclerosis (23). Therefore, we investi-
gated these regions in mice age 40 weeks using OARSI maximum 
and mean OA scores (Figures 2A–E).
We found that while knees of untreated STR/Ort mice at 
age 40 weeks had severe loss of articular cartilage at the medial 
tibial plateau and medial femoral condyle (Figure 2A), STR/Ort 
transgenic mice overexpressing [- 1A]TIMP- 3 with either EF- 
1α[- 1A]TIMP- 3 or Col2a1[- 1A]TIMP- 3 maintained their artic-
ular cartilage (Figures 2B and C). The overall analysis showed 
a significant reduction or prevention of articular cartilage deg-
radation with a decrease of 57% (mean maximum score 1.4; 
P < 0.0001) for the EF- 1α[- 1A]TIMP- 3–transgenic group and a 
decrease of 22% (mean maximum score 2.5; P = 0.0165) for the 
Col2a1[- 1A]TIMP- 3–transgenic group, compared with untreated 
STR/Ort mice (mean maximum score 3.2) (Figure 2D). Similarly, 
mean scores at the medial sites for both overexpressing STR/Ort 
groups were significantly lower than those in the untreated group 
(P = 0.005 for the EF- 1α[- 1A]TIMP- 3–transgenic group and P = 
0.043 for the Col2a1[- 1A]TIMP- 3–transgenic group) (Figure 2E). 
Furthermore, there was a negative correlation between max-
imum OA score and [- 1A]TIMP- 3 expression levels, indicating 
a protective effect of [- 1A]TIMP- 3 when it is expressed at high 
levels (Figures 2F and G). A careful examination of stained sec-
tions revealed that mice expressing high levels of [- 1A]TIMP- 3 
also showed signs of reduced proteoglycan accumulation in the 
cruciate ligaments, restored medial collateral ligament physiol-
ogy, ameliorated osteophyte formation, and abolished synovial 
activation and inflammatory cell infiltration, which are known hall-
marks of OA in this strain (see Supplementary Figure 1, http://
onlinelibrary.wiley.com/doi/10.1002/art.40765/abstract).
The micro- CT data showed that untreated STR/Ort controls 
had severe subchondral sclerosis on the medial side of the knee 
joint (Figures 2H and K). This subchondral bone thickening was 
abrogated both in EF- 1α[- 1A]TIMP- 3–transgenic STR/Ort mice 
and in Col2a1[- 1A]TIMP- 3–transgenic STR/Ort mice (Figures 
2I–K).
Localization of [- 1A]TIMP- 3 and inhibition of aggre-
canases in rescued cartilage. To validate whether the reduc-
tion in articular cartilage degradation and diminished aggrecanase 
cleavage is linked directly to overexpression of [- 1A]TIMP- 3, 
immunohistologic labeling for [- 1A]TIMP- 3 and the aggrecan 
NVTEGE neoepitope was done on adjacent knee joint sections. 
Figure  3A shows a representative coronal section of protected 
knee joint from STR/Ort mice in which [- 1A]TIMP- 3 immunostain-
ing was seen in the adjacent section; [- 1A]TIMP- 3 was evident in 
both menisci and articular cartilage (Figure 3B) and resembled the 
endogenous TIMP- 3 localization with pericellular distribution, as 
previously described (37).
Immunostaining against the NVTEGE neoepitope, an 
ADAMTS catabolic product, revealed that the medial side of 
the joints in OA- prone STR/Ort mice expressing low levels of 
the transgene (Figure  3F) showed little if any labeling for the 
NVTEGE neoepitope due to the extensive cartilage damage 
(verified by Safranin O staining) (Figure 3D) and the likely loss of 
known matrix binding partners for this antigen. This was con-
sistent with NVTEGE- positive labeling (Figure 3F) in the appar-
ently intact sites directly neighboring this damaged OA cartilage 
tissue, into which OA development was likely actively advanc-
ing. The lateral compartment, which is OA- resistant even in the 
STR/Ort strain, retained relatively intact cartilage compared with 
the medial side, yet already exhibited slight proteoglycan loss 
(evidenced by Safranin O staining) (Figure 3E) that colocalized 
with NVTEGE- positive labeling (Figure 3G). In contrast, STR/Ort 
mice expressing high levels of the transgene, which exhibited 
protection against OA and therefore retention of intact carti-
lage in both medial (Figure 3I) and lateral (Figure 3J) knee joint 
compartments, did not show NVTEGE- positive labeling (Figures 
K–M). This was consistent with [- 1A]TIMP- 3–related inhibition of 
ADAMTS- mediated aggrecan degradation.
Selective inhibition of aggrecanases increases bone 
mass in vivo. Given that STR/Ort mice, especially female 
mice (22), show increased trabecular bone mass, we examined 
bone mass (expressed as percentage trabecular bone volume/
total tissue volume [%BV/TV]) using micro- CT in the tibial met-
aphysis of all mice overexpressing the transgene in comparison 
with untreated STR/Ort mice and EF- 1α[- 1A]TIMP- 3–transgenic 
CBA control mice. Consistent with previous findings, nontrans-
genic untreated STR/Ort mice showed significantly increased 
BV/TV compared with CBA mice (22). Intriguingly, tibial BV/TV 
was further increased both in EF- 1α[- 1A]TIMP- 3–transgenic 
mice and in Col2a1[- 1A]TIMP- 3–transgenic mice compared 
with untreated STR/Ort mice (Figure 4A) (representative images 
are shown in Figure 4E), and this was consistent with the other 
micro- CT trabecular bone parameters (see Supplementary Table 
3, http://onlinelibrary.wiley.com/doi/10.1002/art.40765/abstract). 
The extent of this elevation in BV/TV was greater in EF- 1α[- 1A]
TIMP- 3–transgenic mice, presumably due to higher levels of 
[- 1A]TIMP- 3 mRNA overexpression. Subgroup analysis of mice 
expressing low and high levels of [- 1A]TIMP- 3 showed a statisti-
cally significant increase in BV/TV only in STR/Ort mice express-
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ing high levels of [- 1A]TIMP- 3 (Figure  4B). A similar trend was 
observed in EF- 1α[- 1A]TIMP- 3–transgenic CBA control mice 
(Figure 4C).
Data subanalysis based on separation by sex revealed that 
STR/Ort females of both transgenic mouse lines had substan-
tially higher bone mass than untreated controls (Figure 4D). The 
difference was greater in female EF- 1α[- 1A]TIMP- 3–transgenic 
mice expressing high levels of [- 1A]TIMP- 3. Male STR/Ort mice, 
which expressed relatively lower overall levels of [- 1A]TIMP- 3, 
similarly showed higher bone mass in the EF- 1α[- 1A]TIMP- 3–
Figure 3. Localization of the tissue inhibitor of metalloproteinases 3 (TIMP- 3) variant [- 1A]TIMP- 3 and inhibition of aggrecanase activity in 
articular cartilage. A–C, Mice expressing high levels of [- 1A]TIMP- 3, which were protected against osteoarthritis as revealed by Safranin O 
staining (A), showed immunohistochemical staining for anti–TIMP- 3 antibody (arrows in B), which indicated that [- 1A]TIMP- 3 protein was 
translated at high levels. Rabbit IgG was used as negative control (C). D and F, STR/Ort mice expressing low levels of the transgene showed 
cartilage degradation at the medial site (D), which was concomitant with a lack of ADAMTS- derived NVTEGE neoepitope in the adjacent section 
(F), where arrows indicate peripheral neoepitope staining in meniscus (m) and cartilage matrix not yet affected by proteolysis (F). E, G, and H, 
Safranin O staining of the lateral condyle and plateau shows slight proteoglycan loss (E) colocalizing with NVTEGE- positive labeling (circled in 
G). Rabbit IgG was used as negative control (H). I–M, In contrast, in mice expressing high levels of [- 1A]TIMP- 3, cartilage matrix integrity was 
maintained at both medial (I) and lateral (J) sites, with undetectable levels of NVTEGE at either site (K and L), which suggests that ADAMTS- 4/5 
neoepitopes were inhibited by [- 1A]TIMP- 3. Rabbit IgG was used as negative control (M).
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transgenic group compared with untreated STR/Ort mice (Fig-
ure 4D). Finally, cortical bone analysis revealed increased mean 
cortical bone thickness in transgenic STR/Ort mice, demon-
strating that the effect of [- 1A]TIMP- 3 overexpression on bone 
tissue also extends to cortical bone regions (Figures 4F and G).
[- 1A]TIMP- 3 enhances in vitro bone formation. 
The next sets of experiments were devised, first, to determine 
whether the increase in bone mass is coupled with sustained 
changes in osteoblasts isolated from CBA and STR/Ort mice 
with divergent levels of [- 1A]TIMP- 3 transgene overexpres-
Figure 4. Selective inhibition of aggrecanases by [- 1A]TIMP- 3 leads to augmented bone mass in vivo. A, Micro–computed tomography 
trabecular analysis showed that untreated STR/Ort mice have significantly increased bone mass compared with EF- 1α[- 1A]TIMP- 3–transgenic 
CBA mice. EF- 1α[- 1A]TIMP- 3–transgenic mice and Col2a1[- 1A]TIMP- 3–transgenic mice both had significantly increased bone mass compared 
with untreated STR/Ort mice. B, Elevation of bone volume/total tissue volume (BV/TV) was observed only in STR/Ort mice expressing high levels 
of [- 1A]TIMP- 3 (solid symbols), while BV/TV in STR/Ort mice expressing low levels of [- 1A]TIMP- 3 (open symbols) did not differ from BV/TV 
in untreated STR/Ort mice. C, The increase in BV/TV in EF- 1α[- 1A]TIMP- 3–transgenic CBA mice expressing high levels of [- 1A]TIMP- 3 was 
not significant. D, Analysis according to sex showed that STR/Ort females overexpressing either transgene had significantly higher bone mass 
compared with untreated STR/Ort females, while in STR/Ort males an increase in bone mass was observed only in the EF- 1α[- 1A]TIMP- 3–
transgenic group. E, Representative images from groups of STR/Ort female mice are shown, as well as an image representing a group of 
female EF- 1α[- 1A]TIMP- 3–transgenic CBA mice. Lines show the bone volume of interest (VOI) that was analyzed in this experiment. F, The 
same results were observed with cortical bone measurements in the same groups of female mice represented in E. G, Results of cortical bone 
measurements in F are represented visually. In A–D and F, symbols represent individual mice; bars show the mean ± SD. In A–C, ** = P < 
0.01; *** = P < 0.001; **** = P < 0.0001. In D, * = P < 0.05; ** = P < 0.01 versus untreated STR/Ort mice. In F, ** = P < 0.01; **** = P < 0.0001 
versus EF- 1α[- 1A]TIMP- 3–transgenic CBA mice, and †† = P < 0.01; †††† = P < 0.0001 versus untreated STR/Ort mice. See Figure 1 for other 
definitions.
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sion, and second, to test whether enhanced bone mass in 
transgenic mice was related to a developmental program that 
was abrogated by aggrecanase inhibition, or whether changes 
in isolated adult osteoblasts correspond to greater bone 
formation observed in [- 1A]TIMP- 3–overexpressing mice. Pri-
mary osteoblasts were isolated from long bones of CBA and 
STR/Ort EF- 1α[- 1A]TIMP- 3–overexpressing mice, and the 
level of mineralization was assessed using alizarin red S stain-
ing. Results showed that the level of mineralization in isolated 
osteoblasts depended on the level of [- 1A]TIMP- 3 expression 
(Figures  5A and B); higher [- 1A]TIMP- 3 expression levels in 
both STR/Ort and CBA mice were associated with a greater 
extent of mineralization, with osteoblasts from these mice 
forming larger and more  numerous bone nodules compared 
Figure 5. Overexpression of [- 1A]TIMP- 3 increases bone formation both in transgenic mouse–derived and newly infected primary osteoblasts. 
A and B, In vitro bone mineralization assay using alizarin red S staining indicated that long bone osteoblasts derived from EF- 1α[- 1A]TIMP- 3–
transgenic STR/Ort and CBA mice expressing high levels of [- 1A]TIMP- 3 had greater bone- forming capacity than osteoblasts derived from 
mice in these groups expressing low levels of [- 1A]TIMP- 3 (A), forming more and larger bone nodules with a significantly greater percentage 
of stained area (B) at 28 days of mineralization. C and D, Mature osteoblasts isolated from 12- week- old C57BL/6 mice were left untreated, 
mock- infected, or infected with lentiviral [- 1A]TIMP- 3 or native TIMP- 3 and assessed for the extent of mineralization at 21 days (C); osteoblasts 
infected with lentiviral [- 1A]TIMP- 3 showed a significantly greater rate of mineralization compared with untreated or mock- infected osteoblasts 
(D). C–E, In contrast, overexpression of native TIMP- 3 completely stopped mineralization of bone matrix. E, Osteoblasts infected with lentiviral 
[- 1A]TIMP- 3 also showed significantly increased expression of osteogenic gene markers such as alkaline phosphatase (AP), osteocalcin (OC), 
type I collagen (COL1A1), and the transcription factor Runx- 2 compared with untreated or mock- infected osteoblasts. In B, D, and E, symbols 
represent individual mice; bars show the mean ± SD. * = P < 0.05; ** = P < 0.01; **** = P < 0.0001. See Figure 1 for other definitions.
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with osteoblasts derived from mice expressing low levels of 
[- 1A]TIMP- 3.
To further determine whether [- 1A]TIMP- 3 directly affects 
osteoblastic bone formation and mineralization in cells that were 
not previously exposed to the [- 1A]TIMP- 3 transgene in vivo, we 
performed in vitro transduction of adult osteoblasts isolated from 
the long bones of 3- month- old WT mice. We found that [- 1A]
TIMP- 3–transduced osteoblasts formed a significantly increased 
number of mineralized bone nodules compared with untreated 
or mock- infected cells (Figures 5C and D). In order to verify that 
[- 1A]TIMP- 3 exerts different effects compared with native, endog-
enous TIMP- 3, we extended the experiments to include native 
 TIMP- 3. In contrast to transduction with [- 1A]TIMP- 3, native 
TIMP- 3  complete ly abrogated bone formation, consistent with our 
 previous in vivo findings, in which overexpression of Col2a1- driven 
TIMP- 3 resulted in significant reduction in bone mass (28). Simi-
larly, expression of mRNA for alkaline phosphatase, osteocalcin, 
type I collagen, and RUNX- 2, reflecting osteogenic stimulation, 
was found to be elevated in [- 1A]TIMP- 3–transduced osteoblasts 
and suppressed by TIMP- 3 (Figure 5E).
DISCUSSION
The primary aim of our study was to evaluate whether OA 
that arises spontaneously in STR/Ort mice can be ameliorated 
by an aggrecanase inhibitor. We used [- 1A]TIMP- 3, a modified 
TIMP- 3 that was shown to be a “selective” but not a “specific” 
inhibitor against aggrecanases in vitro (30).
We compared knee joints of untreated STR/Ort mice with 
STR/Ort mice that were genetically modified to overexpress [- 1A]
TIMP- 3 either specifically in chondrocytes using the Col2a1 pro-
moter/enhancer Col2a1[- 1A]TIMP- 3 or ubiquitously through len-
tiviral transduction using EF- 1α[- 1A]TIMP- 3. The results clearly 
showed that mice overexpressing [- 1A]TIMP- 3 had protected 
articular cartilage or reduced severity of cartilage degradation 
compared with age- matched, untreated STR/Ort control mice. 
This protection was dependent on expression levels of [- 1A]TIMP- 
3. Maximum and mean OA scores were lower in mice expressing 
high levels of [- 1A]TIMP- 3 and higher in mice expressing low levels 
of [- 1A]TIMP- 3, irrespective of lentiviral or Col2a1- selective deliv-
ery. Our findings demonstrate the critical roles of aggrecanases 
in OA pathophysiology in STR/Ort mice, and they highlight that 
[- 1A]TIMP- 3 can restrict cartilage aggrecan degradation by block-
ing aggrecanase activity, and not only that of ADAMTS- 4 and 
ADAMTS- 5.
Furthermore, our findings indicate that the characteristic 
subchondral bone sclerosis observed in the medial site of epiph-
ysis (19,38) was also significantly reduced in response to [- 1A]
TIMP- 3 overexpression. This suggests that [- 1A]TIMP- 3 may reg-
ulate communication between chondrocytes and bone cells, or 
may indeed have a direct effect on bone through chondrocyte 
transdifferentiation into osteoblasts (39). Alternatively, we need 
to explore the possibility that the primary effect of [- 1A]TIMP- 3 
could be the reduction in subchondral bone sclerosis, which in 
turn improves cartilage stability.
It should be noted that catabolic enzymes such as ADAMTS- 4 
and ADAMTS- 5 are endocytosed by chondrocytes via LRP- 1 
(25,40) which potentially provides protection for cartilage. It is 
also notable that LRP- 1–mediated endocytic clearance of TIMP- 3 
(37,41) and [- 1A]TIMP- 3 is likely to be regulated by LRP- 1 (42). 
This was evident when sulfated glycans (37) inhibited binding of 
TIMP- 3 to LRP- 1 or when mutants of LRP- 1 binding inhibited 
metalloproteinase- mediated degradation of cartilage at lower 
concentrations and for longer periods of time than WT TIMP- 3, 
indicating that their increased half- lives improved their ability to 
protect cartilage (42).
The fact that the endogenous level of TIMP- 3 could be very 
tightly regulated by LRP- 1 at steady state requires an overexpres-
sion system rather than knockout to investigate the role of TIMP- 3 
in vivo, as in the present study in which a significant amount of 
[- 1A]TIMP- 3 protein in mice expressing high levels of the trans-
gene was evident by Western blot, compared with endogenous 
(WT) TIMP- 3. This indicates that the overexpression system over-
comes LRP- 1–mediated endocytic clearance. However, in OA 
cartilage and under inflammatory conditions this clearance sys-
tem is impaired due to increased shedding of LRP- 1 (26). It is 
plausible that LRP- 1 shedding, defective LRP- 1 clearance, or the 
apparent role of glucose transporter 4/LRP- 1 interaction (14) may 
be important contributors to the many defects that increase the 
chances of OA development in STR/Ort mice, but we have not 
investigated this process. Nonetheless, the selective aggrecanase 
inhibitor [- 1A]TIMP- 3 is able to ameliorate the cartilage pathology 
of these mice.
Another major and surprising finding is related to the effect 
of [- 1A]TIMP- 3–mediated aggrecanase inhibition on bone mass. 
STR/Ort mice have an inherent high bone mass phenotype, which 
is linked to increased osteoblast numbers and bone formation 
and reduced osteoclast activity (22). Moreover, STR/Ort females 
exhibit higher bone mass than males, underlying the reported sex-
ual dimorphism in this strain (19,43). Evidence presented herein 
shows that STR/Ort mice expressing high levels of [- 1A]TIMP- 3, 
especially females, had significantly increased trabecular param-
eters and cortical bone thickness, compared with control mice 
and mice expressing low levels of [- 1A]TIMP- 3. We expected the 
opposite effect, since our previous studies demonstrated that high 
levels of WT TIMP- 3 overexpression in mouse cartilage led to lack 
of secondary ossification, and mice with intermediate levels of 
TIMP- 3 had reduced bone mass (28). It has already been shown 
that MMP deficiency (e.g., deficiencies of MMP- 9 and membrane 
type 1 MMP) can lead to developmental skeletal abnormalities 
(44,45). The increased bone mass in STR/Ort mice was mirrored 
in CBA control mice, which suggests that bone augmentation by 
[- 1A]TIMP- 3 is not specific to the STR/Ort strain. Taken together, 
the data suggest that there might be a unique involvement of 
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aggrecanases in bone metabolism, and they highlight that main-
taining skeletal homeostasis depends on balanced matrix remod-
eling by aggrecanases and collagenases.
The findings from in vitro primary osteoblast mineralization 
assays show that osteoblasts isolated from STR/Ort mice highly 
overexpressing [- 1A]TIMP- 3 had a greater bone- forming capac-
ity. This suggests that bone formation is positively influenced by 
inhibition of aggrecanases, which warrants further investigation. 
Most important, this observation was not strain- specific, as in 
vitro infection of WT osteoblasts from young C57BL/6 mice also 
resulted in enhanced bone mineralization and induction of oste-
ogenic pathways when transduced by lentivirus overexpressing 
[- 1A]TIMP- 3 compared with TIMP- 3. Our data suggest that [- 1A]
TIMP- 3 may serve as a novel therapeutic agent in osteoporotic 
bone loss. This notion is supported by findings indicating that 
conditional overexpression of bone- specific TIMP- 1, an MMP- 
only inhibitor, in osteoblasts leads to low bone turnover only in 
females (46).
In conclusion, the spontaneous OA that develops over time in 
STR/Ort mice is driven by aggrecanases, and [- 1A]TIMP- 3 over-
expression can protect against cartilage damage and subchon-
dral bone thickening in this mouse model. In addition, high levels 
of [- 1A]TIMP- 3 overexpression also led to a significant increase 
in bone mass, which highlights a possible dual role of this mol-
ecule as a regulator of cartilage and bone homeostasis. In the 
absence of an effective OA treatment, our novel data show that 
[- 1A]TIMP- 3 or other similar molecules exhibiting selective affinity 
for aggrecanases could be strong candidates for treatment of OA 
and osteoporosis.
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